Biogen presented trial data last year, November, at the Clinical Trials on Alzheimer’s Disease conference in San Diego, for their drug aducanumab.

It was noted that this is a new analysis of data from trials previously stopped prematurely due to limited likelihood of success, so some are advising caution in the interpretation of results.

Read the full story here.